| Dr Maureen Susan Fahey, OD | |
|
8503 W Clearwater Ave, Ste A, Kennewick, WA 99336-3100 | |
| (509) 735-2050 | |
| (509) 735-2288 |
| Full Name | Dr Maureen Susan Fahey |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 33 Years |
| Location | 8503 W Clearwater Ave, Kennewick, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275717696 | NPI | - | NPPES |
| 2032142 | Medicaid | WA | |
| U43761 | Other | WA | UPIN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | WA00003148 (Washington) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dr Maureen Fahey And Associates | 0840367678 | 2 |
News Archive
Gentium S.p.A. announced today interim results from an independent Data Safety Monitoring Board (DSMB) review of the Company's Phase 3 treatment trial of Defibrotide for Severe Veno-Occlusive Disease (VOD).
Northwestern University researchers have demonstrated how the microenvironments of two human embryonic stem cell (hESC) lines (federally approved) induced metastatic melanoma cells to revert to a normal, skin cell-like type with the ability to form colonies similar to hESCs.
A collaborative program aimed at reducing the burden of cancer among Hispanic/Latinos in San Diego and Imperial counties through research and community outreach has received a $13 million grant from the National Cancer Institute, part of the National Institutes of Health. The five-year grant renews funding for a partnership started in 2008 between San Diego State University and Moores Cancer Center at UC San Diego Health.
The U.S. Food and Drug Administration today approved Berinert, the first treatment for acute abdominal attacks and facial swelling associated with a rare and potentially life-threatening genetic disease called hereditary angioedema (HAE).
› Verified 4 days ago
| Provider Name | Dr Maureen Fahey And Associates |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1679675276 PECOS PAC ID: 0840367678 Enrollment ID: O20080922000042 |
News Archive
Gentium S.p.A. announced today interim results from an independent Data Safety Monitoring Board (DSMB) review of the Company's Phase 3 treatment trial of Defibrotide for Severe Veno-Occlusive Disease (VOD).
Northwestern University researchers have demonstrated how the microenvironments of two human embryonic stem cell (hESC) lines (federally approved) induced metastatic melanoma cells to revert to a normal, skin cell-like type with the ability to form colonies similar to hESCs.
A collaborative program aimed at reducing the burden of cancer among Hispanic/Latinos in San Diego and Imperial counties through research and community outreach has received a $13 million grant from the National Cancer Institute, part of the National Institutes of Health. The five-year grant renews funding for a partnership started in 2008 between San Diego State University and Moores Cancer Center at UC San Diego Health.
The U.S. Food and Drug Administration today approved Berinert, the first treatment for acute abdominal attacks and facial swelling associated with a rare and potentially life-threatening genetic disease called hereditary angioedema (HAE).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Maureen Susan Fahey, OD 8503 W Clearwater Ave, Ste A, Kennewick, WA 99336-3100 Ph: (509) 735-2050 | Dr Maureen Susan Fahey, OD 8503 W Clearwater Ave, Ste A, Kennewick, WA 99336-3100 Ph: (509) 735-2050 |
News Archive
Gentium S.p.A. announced today interim results from an independent Data Safety Monitoring Board (DSMB) review of the Company's Phase 3 treatment trial of Defibrotide for Severe Veno-Occlusive Disease (VOD).
Northwestern University researchers have demonstrated how the microenvironments of two human embryonic stem cell (hESC) lines (federally approved) induced metastatic melanoma cells to revert to a normal, skin cell-like type with the ability to form colonies similar to hESCs.
A collaborative program aimed at reducing the burden of cancer among Hispanic/Latinos in San Diego and Imperial counties through research and community outreach has received a $13 million grant from the National Cancer Institute, part of the National Institutes of Health. The five-year grant renews funding for a partnership started in 2008 between San Diego State University and Moores Cancer Center at UC San Diego Health.
The U.S. Food and Drug Administration today approved Berinert, the first treatment for acute abdominal attacks and facial swelling associated with a rare and potentially life-threatening genetic disease called hereditary angioedema (HAE).
› Verified 4 days ago
Alma John Carter, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 8505 W Gage Blvd, Kennewick, WA 99336 Phone: 509-737-8868 | |
James E Kintner, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 3700 W Clearwater Ave, Kennewick, WA 99336 Phone: 509-735-1312 Fax: 506-736-6403 | |
Boyd Edward Robertson, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 7903 W Grandridge Blvd Ste A, Kennewick, WA 99336 Phone: 509-783-0667 Fax: 509-735-7981 | |
Belinda Michelle Badorek, OD Optometrist Medicare: Medicare Enrolled Practice Location: 6515 W Clearwater Ave, Ste 340, Kennewick, WA 99336 Phone: 509-737-2020 Fax: 509-737-1036 | |
Aric D Robertson Od Pllc Optometrist Medicare: Medicare Enrolled Practice Location: 1321 N Columbia Center Blvd, Kennewick, WA 99336 Phone: 509-735-3128 Fax: 509-736-2367 | |
Canyonview Family Eye Care Llc Optometrist Medicare: Medicare Enrolled Practice Location: 4309 W 27th Place, Suite 102, Kennewick, WA 99338 Phone: 509-737-2010 Fax: 509-737-2012 | |
Dr. Virginia O Bice, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 6695 W Rio Grande Ave, Kennewick, WA 99336 Phone: 509-736-0826 Fax: 509-735-6868 |